Vasomune wins FDA fast track designation for lung condition treatment

28 May 2024
www.pharmaceutical-technology.com
Phase 1Clinical ResultFast TrackPhase 2
Vasomune wins FDA fast track designation for lung condition treatment
Preview
Source: Pharmaceutical Technology
AV-001 is designed to improve lung healing in patients by providing a molecular shortcut in blood vessel growth associated with wound closure. Credits: Marko Aliaksandr/Shutterstock.com
Vasomune Therapeutics has announced that its novel investigational medicine, AV-001, has received US Food and Drug Administration (FDA) fast track designation for the treatment of moderate to severe pathogen-induced acute respiratory distress syndrome (ARDS).
Recommended Buyer's Guides
Vasomune wins FDA fast track designation for lung condition treatment
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Top Guide for Drug Delivery Systems
Vasomune wins FDA fast track designation for lung condition treatment
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Top Guide for Cleanrooms and Cleanroom Flooring
As per the 28 May press release, fast track designation was granted based on the high unmet medical need in ARDS. The status allows for earlier interactions with the FDA in the pursuit of accelerated approval and also the possibility to undergo rolling reviews.
ARDS is a life-threatening lung injury that enables fluid to leak into the lungs, causing breathing difficulties and low blood oxygen. According to the press announcement, ARDS is characterised by high mortality rates that can reach up to 46% in patients with severe cases of the disease.
AV-001, a polyethylene glycol (PEG)-clustered Tie2 agonist peptide that was first discovered at Sunnybrook Research Institute at Sunnybrook Hospital, is designed to improve healing in patients by providing a molecular shortcut in blood vessel growth associated with wound closure.
The drug candidate is actively being evaluated in a Phase IIa study (NCT05123755) for the prevention and treatment of hospitalised patients with pneumonia-associated ARDS. The primary endpoint of the study is the safety and tolerability of multiple intravenously administered doses of AV-001 compared to placebo.
See Also:MSD agrees to acquire EyeBio for up to $3bn
Vasomune wins FDA fast track designation for lung condition treatment
Preview
Source: Pharmaceutical Technology
Merck introduces sterility testing solution for pharma quality control
Vasomune wins FDA fast track designation for lung condition treatment
Preview
Source: Pharmaceutical Technology
The Phase I study (NCT04737486) demonstrated a good safety and tolerability profile with strong on-target activity. There were no drug-related discontinuations or deaths, no suspected unexpected severe adverse reactions (SUSARs), and no adverse events of special interest (AESIs), as reported at the 2024 Respiratory Innovation Summit (RIS).
“Vasomune is focused on the persisting unmet needs of people grappling with ARDS and other diseases driven by vascular endothelial instability,” said president and Chief Operating Officer of Vasomune, Dr. Brian Jahns.
The Toronto, Ontario-based biotech is not the only player in the ARDS space. In October 2023, BioAegis Therapeutics was awarded a $20m contract from the US Biomedical Advanced Research and Development Authority (BARDA) for the development of plasma gelsolin for the treatment of ARDS. Also making headway is Healios, which in April 2023, reported positive topline results from the open-label ONE-BRIDGE clinical study of somatic stem cell regenerative therapy MultiStem (HLCM051/invimestrocel) in ARDS patients across Japan.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.